Frankfurt
03.03.25
13:22 Uhr
0,858 Euro
-0,514
-37,46 %
-37,46 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | DIAMYD MEDICAL AB: The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million | 2 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 20.02. | DIAMYD MEDICAL AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico | 2 | Cision News | ||
| 18.02. | Diamyd Medical AB (publ): Diamyd Medical's CFO to leave in 2025 | 56 | GlobeNewswire (Europe) | Diamyd Medical announced today that Anna Styrud, CFO, has decided to step down from her position. During her 15 years as CFO, she has successfully navigated the financial markets and played a key role... ► Artikel lesen | |
| 12.02. | Diamyd Medical AB: Diamyd Medical announces expanded financial support from Breakthrough T1D | 270 | PR Newswire | STOCKHOLM, Feb. 12, 2025 /PRNewswire/ -- Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world's leading Type 1 Diabetes... ► Artikel lesen | |
| 12.02. | DIAMYD MEDICAL AB: DiamydMedical announces expanded financial support from Breakthrough T1D | 4 | Cision News | ||
| 29.01. | Diamyd Medical AB (publ): Quarterly Report 1 24/25 | 51 | GlobeNewswire (Europe) | September 2024 - November 2024, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical's B-share is traded... ► Artikel lesen | |
| 21.01. | DIAMYD MEDICAL AB: South Korea to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 2 | Cision News | ||
| 13.01. | Diamyd Medical AB: Diamyd Medical updates U.S. market potential for Diamyd | 356 | PR Newswire | STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- Diamyd Medical has released an updated analysis of the commercial potential for its lead product candidate, the precision immunotherapy Diamyd® (rhGAD65/alum)... ► Artikel lesen | |
| 10.01. | Diamyd Medical AB: Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd following FDA Type C Meeting | 1.307 | PR Newswire | STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
| 09.01. | DIAMYD MEDICAL AB: Renowned immunology investigator, Alice Long, joins Diamyd Medical's Scientific Advisory Board | 2 | Cision News | ||
| 07.01. | Diamyd Medical AB (publ): New publication highlights safety and potential benefits of redosing Diamyd precision medicine for Type 1 Diabetes | 120 | GlobeNewswire (Europe) | Diamyd Medical announces the publication of the article titled "Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial" in the peer-reviewed journal International... ► Artikel lesen | |
| 23.12.24 | DIAMYD MEDICAL AB: Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical's Scientific Advisory Board | 1 | Cision News | ||
| 13.12.24 | Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process | 362 | PR Newswire | STOCKHOLM, Dec. 13, 2024 /PRNewswire/ -- Diamyd Medical today announced a positive in-person Type C meeting with the U.S. Food and Drug Administration (FDA), where alignment was achieved... ► Artikel lesen | |
| 05.12.24 | Bulletin from Annual General Meeting of Diamyd Medical AB | 2 | Cision News | ||
| 03.12.24 | DIAMYD MEDICAL AB: Annual Report 2023/2024 | 2 | Cision News | ||
| 25.11.24 | DIAMYD MEDICAL AB: Article published by ASSET, coordinated by Diamyd Medical, advocates for national screening programs in Sweden for early detection of Type 1 Diabetes | 1 | Cision News | ||
| 21.11.24 | Diamyd Medical AB: Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial | 285 | PR Newswire | STOCKHOLM, Nov. 21, 2024 /PRNewswire/ -- 180 patients have now been recruited in the precision medicine Phase 3 trial DIAGNODE-3, exceeding the recruitment target set for the planned early... ► Artikel lesen | |
| 15.11.24 | DIAMYD MEDICAL AB: Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical | 1 | Cision News | ||
| 14.11.24 | DIAMYD MEDICAL AB: Diamyd Medical recognizes World Diabetes Day | 1 | Cision News | ||
| 14.11.24 | DIAMYD MEDICAL AB: Information about the Annual Report 2023/2024 | 2 | Cision News |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 201,70 | -0,05 % | AKTIONÄR-Depotwert Gubra: Hammer-Deal mit AbbVie - die Details! | Paukenschlag zum Wochenstart: AKTIONÄR-Depotwert Gubra hat eine Lizenzvereinbarung mit dem Pharma-Riesen AbbVie unter Dach und Fach gebracht. Die Amerikaner sichern sich die Rechte an einem Amylin-Projekt... ► Artikel lesen | |
| INNOCAN PHARMA | 0,130 | -0,38 % | InnoCan Pharma: Großaktionär erhöht den Bestand auf über 20%?! | ||
| ABBOTT LABORATORIES | 133,46 | -0,24 % | Unified Investment Management Takes $368,000 Position in Abbott Laboratories (NYSE:ABT) | ||
| ZOETIS | 161,50 | -0,75 % | Stifel maintains Buy on Zoetis stock with $180 target | ||
| CRESCO LABS | 0,800 | +1,78 % | Cresco Labs Inc. to Report Fourth Quarter 2024 Financial Results on March 12, 2025 Business Wire | ||
| CSPC PHARMA | 0,589 | +5,14 % | Die Aktie der CSPC Pharmaceutical Group läuft schlechter: Große Kursverluste! (0,582 €) | Zu den großen Verlierern am Aktienmarkt zählt heute die CSPC Pharmaceutical Group-Aktie . Der Titel verbilligt sich am Freitag deutlich. Mit einem Verlust von 5,52 Prozent gehört heute der Anteilsschein... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 7,460 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash | Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities... ► Artikel lesen | |
| AMARIN | 0,520 | +5,26 % | Amarin Corporation plc: Amarin Marks Key Milestone for VASCEPA/VAZKEPA (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol ... | -- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,794 | +3,25 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata | SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AA... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 123,75 | +2,02 % | Axsome Therapeutics gets FDA support to submit sNDA for its Alzheimer's disease agitation treatment | ||
| WUXI BIOLOGICS | 2,805 | +1,87 % | Aktie von WuXi Biologics unter Druck: Kurs fällt um 11,75 Prozent (2,876 €) | An der Börse fällt aktuell der Anteilsschein von WuXi Biologics negativ auf. Der Kurs der Aktie sackt kräftig ab. Jahreschart der WuXi Biologics Inc-Aktie, Stand 24.02.2025 Zu den großen Verlierern... ► Artikel lesen | |
| JAGUAR HEALTH | 0,570 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value | Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion diseaseFDA... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 17,335 | +0,03 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen | |
| DAIICHI SANKYO | 22,840 | +0,04 % | Daiichi Sankyo: ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy | Recommendation based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year
Daiichi... ► Artikel lesen | |
| TRULIEVE CANNABIS | 3,992 | -1,24 % | Trulieve Cannabis Corp.: Trulieve Reports Fourth Quarter and Full Year 2024 Results Highlighting Margins and Cash Flow | Fourth quarter revenue of $301 million, up 5% year over year, exceeding guidance
Gross margin of 62%, compared to 54% during the fourth quarter of 2023
... ► Artikel lesen |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -37,46 % bei einem Aktienkurs von 0,858 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.
